Allergic Rhinitis Market Overview
The Global Allergic Rhinitis Market Size is expected to reach USD 22.32 Billion by 2033. The global Allergic Rhinitis industry size accounted for USD 14.75 billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 4.12% from 2023 to 2033.Allergic rhinitis is a chronic condition that can be seasonal or perennial, depending on the type of allergen and individual sensitivity. Seasonal allergic rhinitis is usually triggered by airborne allergens that are prevalent during specific times of the year, such as tree pollen in the spring, grass pollen in the summer, and weed pollen in the fall. Perennial allergic rhinitis, on the other hand, can occur year-round and is often triggered by indoor allergens, such as dust mites, pet dander, and mold spores. Treatment for allergic rhinitis may include allergen avoidance, medication such as antihistamines, decongestants, nasal cortico steroids, and immune therapy (allergy shots) for severe cases. It’s important to consult a healthcare professional for an accurate diagnosis and appropriate treatment plan tailored to individual needs.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a multi-faceted impact on the Allergic Rhinitis market, with changes in patient behavior, disruptions in healthcare services, economic challenges, and shifts in research and development efforts. The full extent of the impact may continue to evolve as the pandemic situation changes and further research is conducted. It is important to consult with healthcare professionals and stay updated with the latest information and guidelines for the management of Allergic Rhinitis during the pandemic.
Allergic Rhinitis Market Dynamics
The major factors that have impacted the growth of Allergic Rhinitis are as follows:
Growing awareness and diagnosis of allergic
Awareness about allergic rhinitis has been raised through various channels, including public health campaigns, educational initiatives by healthcare organizations, and increased media coverage. Patients and healthcare providers are now better informed about the common symptoms of allergic rhinitis, such as sneezing, itching, nasal congestion, and a runny nose, which prompts them to seek medical attention for a proper diagnosis.Early diagnosis of allergic rhinitis allows for timely initiation of treatment, which can help in managing symptoms and preventing complications. It also helps in identifying triggers and implementing appropriate allergen avoidance strategies. As a result, there is a higher demand for medications and other treatment options to effectively manage allergic rhinitis, which drives the growth of the Allergic Rhinitis market.
Side effects and safety concerns
Some of the medications used for allergic rhinitis, such as nasal corticosteroids and antihistamines, may have side effects such as drowsiness, dryness of the mouth or nose, and other adverse effects. This may limit their use in certain patient populations, such as children, elderly individuals, or those with specific health conditions. Safety concerns associated with the long-term use of medications may also impact patient compliance and adherence to treatment regimens, which could be a restraint for the market.
Increasing adoption of immuno therapy
Immuno therapy, such as subcutaneous or sublingual allergen immuno therapy, has shown promising results in managing allergic rhinitis by addressing the underlying immune response to allergens. With increasing research and clinical evidence supporting the safety and efficacy of immuno therapy, there is an opportunity for wider adoption of immuno therapy as a long-term treatment option for allergic rhinitis. This can drive the growth of the market and provide additional treatment options for patients.
Allergic Rhinitis Segment Overview
By Drug Class
Based on the Drug Class, the market is segmented based on Antihistamines, Intranasal cortico steroids, and Immuno therapies. During the projection period, the Antihistaminessegmentis expected to hold the largest market share.Antihistamines are commonly used for the treatment of Allergic Rhinitis, which is a condition characterized by inflammation of the nasal passages due to an allergic reaction. Antihistamines work by blocking the action of histamine, a chemical released by the immune system in response to allergens, thus relieving symptoms such as sneezing, itching, and a runny nose.
By Route of Administration
Based on the Route of Administration, the market has been divided into Oral, Parental, and Intranasal. The Oral segment is expected to hold the largest market share.Oral medications, including antihistamines and other classes of drugs, are commonly used for the treatment of Allergic Rhinitis. Oral antihistamines are available over-the-counter (OTC) or with a prescription, and they are typically used for mild to moderate symptoms of Allergic Rhinitis, such as sneezing, itching, and a runny nose. They work by blocking the action of histamine, a chemical released by the immune system in response to allergens.
Based on Form, the market has been divided into Solid and Liquid.The Solid segment is expected to hold the largest market share.Solid dosage forms, including oral tablets and capsules, are commonly used for the treatment of Allergic Rhinitis. Oral medications, such as antihistamines, decongestants, and nasal cortico steroids, are available in solid dosage forms and are typically used for mild to moderate symptoms of Allergic Rhinitis, including sneezing, itching, and a runny nose.
Global Allergic Rhinitis Market Share, by Segmentation
Based on region, the global MHealth market has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America is projected to dominate the use of the market followed by the Asia-Pacific and Europe regions.
North America Market
North America holds a significant share of the global allergic rhinitis market. Allergic rhinitis, commonly known as hay fever, is a condition characterized by inflammation of the nasal passages due to an immune response triggered by allergens such as pollen, dust mites, pet dander, and mold spores. In North America, the prevalence of allergic rhinitis is relatively high, with a large number of people suffering from seasonal or perennial allergies. The region has a well-established healthcare infrastructure and advanced diagnostic and treatment options, which contribute to the dominance of North America in the allergic rhinitis market.
The Asia-Pacific region is projected to be a prominent growth market for the allergic rhinitis market. Allergic rhinitis, commonly known as hay fever, is a condition characterized by inflammation of the nasal passages due to an immune response triggered by allergens such as pollen, dust mites, pet dander, and mold spores. In recent years, there has been an increasing awareness of allergic rhinitis in the Asia-Pacific region, leading to a higher demand for diagnosis and treatment options. Rapid urbanization, changing lifestyles, and environmental factors such as increasing pollution levels and exposure to allergens are contributing to the rising prevalence of allergic rhinitis in the region. Furthermore, the growing middle-class population with higher disposable incomes and improved access to healthcare services are driving the demand for allergic rhinitis medications and treatments in the Asia-Pacific region. Increasing investments in healthcare infrastructure andthe rising adoption of advanced diagnostic and treatment technologies are also supporting the growth of the allergic rhinitis market in the region.
The market comprises tier-1, tier-2, and local players. With their wide product portfolios, tier-1 and tier-2 players have a global reach. Since their strategic innovations and broad regional presence, companies such as Glaxo Smith Kline,Merck & Co, Johnson & Johnson, and Sanofi lead the global Allergic Rhinitis business. To increase their market position and attract a wide consumer base, the businesses are employing various strategies, such as growth, product releases, and alliances.
- Glaxo Smith Kline
- Meda Pharmaceuticals
- Merck & Co
- Boehringer Ingelheim
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd
- Alcon (Novartis AG)
November 2022: Alcon announced the acquisition of Aerie Pharmaceuticals, Inc. This acquisition will assist Alcon in strengthening its ophthalmic medicines portfolio, which already includes several commercial products and others in the development stage.
September 2022: Glenmark Pharmaceuticals’ Ryaltris nasal spray. The utilization of this cutting-edge therapeutic approach is employed to treat severe seasonal allergic rhinitis as well as other eye problems. Through its subsidiaries Glenmark Specialty SA and Bausch Health Companies Inc., the permission is secured.
March 2021: ALK announced that the FDA had approved the use of short ragweed pollen allergen extract for the treatment of patients with short ragweed pollen-induced allergic rhinitis who are 5 to 65 years old.
Scope of the Report
Global Allergic Rhinitis Market, by Drug Class
- Intranasal corticosteroids
Global Allergic Rhinitis Market, by Route of Administration
Global Allergic Rhinitis Market, by Form
Global Allergic Rhinitis Market, by Region
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of SouthAmerica
- Middle East &Africa
- Saudi Arabia
- Rest of Middle East & Africa
4.12% CAGR (2023-2033)
2023 to 2033
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Drug Class,Route of Administration,Form
North America, Europe, Asia-Pacific, Latin America, Middle East, Africa
GlaxoSmithKline, Sanofi, ALK-Abell, Meda Pharmaceuticals, Merck & Co., Boehringer Ingelheim, AstraZeneca, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Alcon (Novartis AG)
Key Market Opportunities
Increasing adoption of immunotherapy
Key Market Drivers
Growing awareness and diagnosis of allergic rhinitis
REPORT CONTENT BRIEF:
- High-level analysis of the current and future Allergic Rhinitis market trends and opportunities
- Detailed analysis of current market drivers, restraining factors, and opportunities in the future
- Allergic Rhinitis market historical market size for the year 2021, and forecast from 2023 to 2033
- Allergic Rhinitis market share analysis at each product level
- Competitor analysis with a detailed insight into its product segment, financial strength, and strategies adopted.
- Identifies key strategies adopted including product launches and developments, mergers and acquisitions, joint ventures, collaborations, and partnerships as well as funding taken and investment done, among others.
- To identify and understand the various factors involved in the global Allergic Rhinitis market affected by the pandemic
- To provide a detailed insight into the major companies operating in the market. The profiling will include the financial health of the company’s past 2-3 years with segmental and regional revenue breakup, product offering, recent developments, SWOT analysis, and key strategies.
What is the study period of this market?
The study period of the global Allergic Rhinitis market is 2022- 2033
What is the growth rate of the global Allergic Rhinitis market?
The global Allergic Rhinitis market is growing at a CAGR of ~4.12% over the next 10 years
Which region has the highest growth rate in the market of Allergic Rhinitis?
Asia Pacific is expected to register the highest CAGR during 2023-2033
Which region has the largest share of the global Allergic Rhinitis market?
North America holds the largest share in 2022
Who are the key players in the global Allergic Rhinitis market?
GlaxoSmithKline, Sanofi, ALK-Abell, Meda Pharmaceuticals, Merck & Co., Boehringer Ingelheim, AstraZeneca, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Alcon (Novartis AG)are the major companies operating in the market.
Do you offer Post Sale Support?
Yes, we offer 16 hours of analyst support to solve the queries
Do you sell particular sections of a report?
Yes, we provide regional as well as country-level reports. Other than this we also provide a sectional report. Please get in contact with our sales representatives.